8-K: SeaStar Medical Reports Q3 2025 Growth, Strong QUELIMMUNE Sales

SeaStar Medical announced strong third-quarter 2025 financial results and significant progress in its clinical trials and commercial product adoption, including a $12.4 million capital raise.

Summary

• Reported Q3 2025 financial results and business updates, showing progress on multiple fronts.
• Added three new top-rated children's hospitals to the QUELIMMUNE customer base, with Q4 orders to date already exceeding total Q3 orders.
• QUELIMMUNE therapy demonstrated positive survival results in 21 pediatric patients from the SAVE Surveillance Registry, with 76% surviving through 60 days and 71% through 90 days, validating a 50% reduction in loss of life.
• Interim analysis of the NEUTRALIZE-AKI pivotal trial showed a positive signal toward efficacy and zero device-related safety issues.
• Enrollment target for NEUTRALIZE-AKI trial adjusted from 200 to approximately 339 patients, with completion anticipated near the end of 2026.
• Enrolled 21 additional patients in NEUTRALIZE-AKI, bringing total enrollment to 146 of 339 anticipated patients.
• Initiated the first clinical site for the NEUTRALIZE-CRS trial for patients with CHF and CRS awaiting LVAD implantation, targeting 20 patients.
• Raised $12.4 million through equity offerings and warrant exercises in Q3 2025, significantly strengthening the balance sheet and extending the financial runway.
• Net revenue for Q3 2025 increased to $0.2 million from $0.1 million in Q3 2024.
• Net loss for Q3 2025 decreased to $3.5 million ($0.13 per share) from $4.5 million ($1.10 per share) in Q3 2024.
• Cash balance at September 30, 2025, was $13.8 million, a substantial increase from $1.8 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The company demonstrated strong operational execution with increased product adoption, positive clinical trial interim results, and a substantial capital raise that significantly improved its cash position. While still incurring losses, the reduction in net loss and increased revenue are positive signs. The increase in trial enrollment size and extended timeline for NEUTRALIZE-AKI is a minor concern but offset by positive efficacy signals.

Positives

• Net revenue increased to $0.2 million in Q3 2025 from $0.1 million in Q3 2024, reflecting growing commercial sales of QUELIMMUNE.
• Net loss significantly reduced to $3.5 million in Q3 2025 from $4.5 million in Q3 2024.
• Cash balance dramatically improved to $13.8 million at September 30, 2025, from $1.8 million at December 31, 2024.
• Successfully raised $12.4 million through equity offerings and warrant exercises, strengthening the balance sheet and extending the financial runway.
• Expanded QUELIMMUNE customer base by securing three new top-rated children's hospitals.
• Demonstrated strong commercial traction for QUELIMMUNE, with Q4 orders to date already exceeding total Q3 orders.
• Preliminary real-world data from the SAVE Surveillance Registry showed positive survival results for QUELIMMUNE therapy (76% at 60 days, 71% at 90 days) in pediatric AKI patients, validating a 50% reduction in loss of life.
• Interim analysis of the NEUTRALIZE-AKI pivotal trial by the independent Data Safety Monitoring Review Board (DSMB) showed a positive signal toward efficacy and zero device-related safety issues.
• Reduced research and development expenses to $1.9 million in Q3 2025 from $2.3 million in Q3 2024.
• Reduced general and administrative expenses to $1.9 million in Q3 2025 from $2.2 million in Q3 2024.
• Initiated the first clinical site for the NEUTRALIZE-CRS clinical trial, opening a new potential therapeutic area.

Negatives

• Despite revenue growth and reduced losses, the company continues to operate at a net loss of $3.5 million for Q3 2025.
• Cost of goods sold increased to $14 thousand in Q3 2025 from $0 in Q3 2024, reflecting the commercialization of QUELIMMUNE but also a new operational cost.
• Weighted-average shares outstanding increased significantly to 26.4 million in Q3 2025 from 4.1 million in Q3 2024, indicating substantial dilution from recent capital raising activities.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.

Future Outlook

The company anticipates completing enrollment for its NEUTRALIZE-AKI pivotal clinical trial near the end of 2026. It expects continued strong QUELIMMUNE sales, with Q4 orders already exceeding Q3. The NEUTRALIZE-CRS trial, if successful, could lead to an FDA marketing application. The company aims to focus cash resources on the adult AKI market, which is 50 times larger than the pediatric AKI market.

Management Comments

• "We made strong progress on multiple fronts which we believe position us well for our future growth."
• "We added three top-ranked children's medical centers to our growing customer base, and also reported very impressive survival results for the use of the QUELIMMUNE therapy in the treatment of 21 pediatric patients in a commercial setting."
• "In the first half of the fourth quarter, we are extremely pleased to see very strong QUELIMMUNE sales, with orders to date already exceeding orders for the entire third quarter."
• "We completed the interim analysis, enabling us to understand early safety data and trends toward efficacy for our NEUTRALIZE-AKI pivotal clinical trial of the selective cytopheretic device (SCD) therapy in adult patients with AKI."
• "We continued our disciplined effort to reduce costs while achieving strong operational results and we raised over $12 million to strengthen our balance sheet and extend our financial runway."

Industry Context

SeaStar Medical operates in the critical care medical device sector, specifically targeting acute kidney injury (AKI) and cardiorenal syndrome (CRS), conditions with high mortality and significant healthcare costs. The company's focus on immunomodulation via its Selective Cytopheretic Device (SCD) therapy positions it in a niche aiming to address destructive hyperinflammation, a common factor in organ failure. The pediatric AKI market, while smaller, provides a commercial foothold, while the adult AKI market represents a significantly larger opportunity. The FDA's Breakthrough Device Designation for SCD therapy highlights its potential to address unmet medical needs, aligning with broader industry trends towards innovative solutions for severe, life-threatening conditions.

Comparison to Industry Standards

• The QUELIMMUNE therapy's preliminary results showing 76% survival through 60 days and 71% through 90 days in critically ill pediatric AKI patients with sepsis, validating a 50% reduction in loss of life compared to historical data, suggests a significant improvement over standard of care in this ultra-rare condition.
• The adult AKI market requiring CRRT is stated to be an annual U.S. market opportunity 50 times larger than the U.S. pediatric AKI market, indicating a substantial growth potential if the NEUTRALIZE-AKI trial is successful. No specific comparable companies or projects are mentioned in the filing to benchmark against.

Stakeholder Impact

• Shareholders: Experienced significant dilution due to equity offerings and warrant exercises, but the capital raise strengthens the company's financial position and extends its runway, potentially reducing immediate future dilution risk. Positive clinical and commercial progress could increase long-term value.
• Patients (Pediatric AKI): Continued access to QUELIMMUNE therapy through expanding hospital adoption and validated positive survival outcomes.
• Patients (Adult AKI & CHF/CRS): Progress in clinical trials (NEUTRALIZE-AKI, NEUTRALIZE-CRS) offers hope for future treatment options for life-threatening conditions with unmet needs.
• Employees: Continued operations and clinical development suggest job stability and potential growth opportunities.
• Customers (Hospitals): Increased adoption of QUELIMMUNE indicates growing trust and utility of the product.
• Creditors: Strengthened balance sheet and extended financial runway reduce immediate credit risk.

Next Steps

• Continue enrollment for the NEUTRALIZE-AKI pivotal clinical trial, aiming for completion near the end of 2026.
• Continue to add new clinical sites for the NEUTRALIZE-AKI trial.
• Continue enrollment for the NEUTRALIZE-CRS clinical trial (20 patients).
• Potentially pursue a marketing application to the U.S. FDA for NEUTRALIZE-CRS if the trial is successful.
• Focus cash resources on the development of SCD therapy for adult patients with AKI.
• Host a webcast call on November 13, 2025, at 4:30 p.m. Eastern Time to discuss results and updates.

Key Dates

Recommendation

The company shows promising clinical progress with positive interim data for NEUTRALIZE-AKI and strong commercial traction for QUELIMMUNE, including a significant increase in Q4 orders. The successful capital raise has substantially improved the cash position, extending the financial runway and reducing immediate liquidity concerns. However, the company remains pre-profitability, and the NEUTRALIZE-AKI trial's increased patient count and extended timeline introduce some uncertainty and continued cash burn. The significant share dilution from the capital raise is also a factor. Given the positive operational momentum balanced against the ongoing clinical development risks and dilution, a "hold" recommendation is appropriate for investors to monitor further clinical trial results and continued commercial scaling before making a more definitive long-term commitment.

Keywords

Acute Kidney Injury (AKI), QUELIMMUNE, Selective Cytopheretic Device (SCD), Sepsis, Pediatric AKI, Adult AKI, NEUTRALIZE-AKI, Cardiorenal Syndrome (CRS), Heart Failure, FDA Approval, Clinical Trials, Medical Devices, Healthcare, Organ Failure, Biotechnology